L-2-Hydroxyglutaric Aciduria is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Path: /diseases/l-2-hydroxyglutaric-aciduria
L-2-Hydroxyglutaric aciduria (L2GA) is a rare autosomal recessive neurometabolic disorder characterized by the accumulation of L-2-hydroxyglutaric acid in body fluids and tissues, particularly in the brain. The disease is caused by deficiency of L-2-hydroxyglutarate dehydrogenase (L2HGDH), an enzyme involved in the metabolism of L-2-hydroxyglutarate, a metabolite produced during normal cellular processes. This accumulation leads to progressive neurodegeneration, with clinical manifestations including cerebellar ataxia, intellectual disability, and characteristic MRI findings of leukoencephalopathy.
L-2-hydroxyglutaric aciduria is caused by homozygous or compound heterozygous mutations in the L2HGDH gene (chromosome 14q22.1), which encodes the enzyme L-2-hydroxyglutarate dehydrogenase. This enzyme catalyzes the oxidation of L-2-hydroxyglutarate to 2-ketoglutarate (alpha-ketoglutarate) in the mitochondrial matrix, using FAD as a cofactor.
L2GA follows an autosomal recessive inheritance pattern. Parents of an affected individual are typically asymptomatic carriers, with a 25% recurrence risk for subsequent pregnancies. The disease has been reported in various ethnic groups, with higher prevalence in populations with consanguinity.
L-2-hydroxyglutaric aciduria is an extremely rare disorder, with approximately 100 cases reported in the literature worldwide. The exact prevalence is unknown but estimated to be less than 1 per million population.
The primary metabolic defect in L2GA involves impairment of L-2-hydroxyglutarate dehydrogenase activity:
-
L-2-hydroxyglutarate is produced endogenously through various metabolic processes, including:
- Lysine degradation via the pipecolic acid pathway
- Hydroxylation of 2-ketoglutarate in a side reaction of various enzymes
-
L2HGDH normally converts L-2-hydroxyglutarate to 2-ketoglutarate:
- This reaction is part of the mitochondrial metabolic network
- 2-ketoglutarate enters the TCA cycle for further metabolism
-
In L2GA, the enzymatic deficiency leads to:
- Accumulation of L-2-hydroxyglutarate in the brain and other tissues
- Elevated levels in cerebrospinal fluid, plasma, and urine
- Secondary effects on brain development and function
The mechanisms by which L-2-hydroxyglutarate accumulation causes neurodegeneration include:
- Oxidative stress: L-2-hydroxyglutarate can generate reactive oxygen species
- Energy metabolism impairment: Secondary mitochondrial dysfunction
- Epigenetic effects: 2-ketoglutarate is a cofactor for DNA demethylases; accumulation of L-2-hydroxyglutarate may interfere with epigenetic regulation
- Excitotoxicity: Potential effects on glutamate signaling
Postmortem studies show:
- Diffuse cerebral leukoencephalopathy
- Vacuolation of white matter
- Cerebellar atrophy, particularly of the dentate nucleus
- Variable neuronal loss
- Myelin abnormalities
Symptoms typically begin in early childhood, usually between ages 1-5 years, though milder forms may present later.
Neurological Symptoms:
-
Cerebellar ataxia: The most consistent feature, characterized by:
- Gait instability and truncal ataxia
- Limb incoordination
- Dysarthria (slurred speech)
- Nystagmus
-
Cognitive impairment:
- Variable intellectual disability (mild to severe)
- Developmental delays
- Learning difficulties
-
Movement disorders:
- Dystonia
- Chorea
- Tremor
- Myoclonus (in some cases)
-
Seizures: Occur in approximately 30-50% of patients
Systemic Features:
- Macrocephaly (enlarged head circumference) in some patients
- Short stature may be present
- No significant organ involvement outside the nervous system
L2GA is typically slowly progressive:
- Motor symptoms often worsen over years
- Cognitive decline may be gradual or stepwise
- Life expectancy varies; many patients survive into adulthood
- Some patients experience periods of acute regression, sometimes triggered by illness or metabolic stress
Urine Organic Acid Analysis:
- Elevated urinary excretion of L-2-hydroxyglutarate is the biochemical hallmark
- Levels are typically markedly elevated (10-100x normal)
- Analysis by GC-MS or LC-MS/MS is the standard method
Plasma and CSF Analysis:
- Elevated L-2-hydroxyglutarate in plasma
- Even higher levels in cerebrospinal fluid
- Normal levels of other organic acids help distinguish from related disorders
MRI Findings:
- Diffuse, symmetric cerebral leukoencephalopathy
- T2/FLAIR hyperintensities in the deep white matter
- Relative preservation of subcortical U-fibers early in disease
- Cerebellar involvement, particularly of the dentate nuclei
- Brainstem may be affected in advanced disease
- Progressive atrophy over time
- Sequencing of the L2HGDH gene confirms the diagnosis
- Identifies pathogenic variants (missense, nonsense, splice-site, deletions)
- Carrier testing for at-risk family members
- Prenatal diagnosis possible for families with known mutations
L2GA must be distinguished from:
- D-2-hydroxyglutaric aciduria (caused by D2HGDH mutations; different clinical phenotype)
- Combined D,L-2-hydroxyglutaric aciduria (caused by SLC25A1 mutations)
- Other leukodystrophies (Metachromatic leukodystrophy, Krabbe disease)
- Cerebral palsy and other developmental disorders
There is no cure for L2GA. Treatment is supportive and focuses on symptom management:
Seizure Control:
- Standard antiepileptic medications
- Response varies among patients
Movement Disorder Management:
- Dystonia: Baclofen, anticholinergics, botulinum toxin injections
- Tremor: Beta-blockers, primidone
Supportive Therapies:
- Physical therapy for gait training and spasticity management
- Occupational therapy for ADL training
- Speech therapy for dysarthria
- Educational support and special education services
Nutritional Support:
- Regular monitoring of growth and nutritional status
- Dietitian consultation as needed
Dietary Interventions:
- Some reports of benefit from dietary restriction of lysine (precursor to L-2-hydroxyglutarate)
- Carnitine supplementation has been tried
Enzyme Replacement: Not currently available
Gene Therapy: Under investigation in preclinical models
The prognosis for individuals with L2GA is variable:
- Early-onset severe form: Rapid progression in childhood
- Classic form: Slow progression over decades
- Mild/late-onset form: May have stable or slowly progressive disease
Life expectancy is variable:
- Many patients survive into adulthood
- Severe cases may have shortened lifespan
- Quality of life can be significantly affected by motor and cognitive impairments
Current research areas include:
- Natural history studies to characterize disease progression
- Development of biomarkers for monitoring
- Gene therapy approaches using viral vectors
- Small molecule therapies targeting metabolic pathways
- Understanding genotype-phenotype correlations
- Guo Q, Löhr T, Giavalisco P et al., A Pathogenic L2HGDH Variant Impairs Mitochondrial Targeting and Enzyme Activity (2025) - Genes (Basel)
- Engin Erdal A, Özbey SZ, Civelek Ürey GB et al., Genetic, neuroimaging, and clinical characteristics of a cohort of patients (2025) - J Pediatr Endocrinol Metab
- Radhakrishnan DM, Kaur R, Prajapati B et al., L-2-Hydroxyglutaric Aciduria Complicated by Cerebral Neoplasm (2025) - Mov Disord Clin Pract
- Lipiński P, Ciara E, Bogdańska A et al., Riboflavin treatment in L-2-hydroxyglutaric aciduria: report on a pediatric case (2025) - J Appl Genet
- Shimozato M, Sakurai T, Yaguchi T et al., A case of L-2-hydroxyglutaric aciduria diagnosed with involuntary movements (2025) - Rinsho Shinkeigaku